Notify me when Stonepine Capital Management, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 61 | $125,582,558 | +$33,161,495 | -$38,052,621 | -$4,891,126 | VSTM, ADMA, EOLS, ZVRA, IKT | 13F-HR | 13 Feb 2026, 16:54 |
| Q3 2025 | 58 | $123,007,632 | +$43,172,953 | -$35,856,532 | +$7,316,421 | VSTM, ADMA, EOLS, ZVRA, NKTR | 13F-HR | 13 Nov 2025, 16:45 |
| Q2 2025 | 58 | $101,512,543 | +$27,243,781 | -$29,100,020 | -$1,856,239 | ADMA, EOLS, ZVRA, VSTM, INDV | 13F-HR | 13 Aug 2025, 16:31 |
| Q1 2025 | 66 | $82,978,136 | +$15,989,123 | -$16,939,051 | -$949,928 | EOLS, OPTN, ZVRA, VSTM, URGN | 13F-HR | 14 May 2025, 16:03 |
| Q4 2024 | 52 | $123,887,533 | +$31,858,433 | -$59,325,703 | -$27,467,270 | ADMA, EOLS, TELA, GLPG, ZVRA | 13F-HR | 13 Feb 2025, 17:39 |
| Q3 2024 | 38 | $158,247,836 | +$51,811,985 | -$39,382,728 | +$12,429,257 | ADMA, EOLS, GLPG, JAZZ, RPRX | 13F-HR | 13 Nov 2024, 16:49 |
| Q2 2024 | 25 | $109,604,967 | +$20,270,353 | -$41,274,125 | -$21,003,772 | ADMA, ALIM, EOLS, GLPG, RVNC | Restatement | 20 Aug 2024, 20:59 |
| Q1 2024 | 20 | $126,057,631 | +$30,064,681 | -$172,144,607 | -$142,079,926 | EOLS, ADMA, ALIM, GLPG, RVNC | 13F-HR | 14 May 2024, 18:12 |
| Q4 2023 | 16 | $231,228,198 | +$2,275,775 | -$91,767,945 | -$89,492,170 | EOLS, ADMA, AMLX, QDEL, ALIM | 13F-HR | 13 Feb 2024, 16:25 |
| Q3 2023 | 23 | $301,032,343 | +$76,220,373 | -$20,194,195 | +$56,026,178 | QDEL, EOLS, AMLX, ADMA, GLPG | 13F-HR | 13 Nov 2023, 16:02 |
| Q2 2023 | 2 | $11,032,122 | $0 | $0 | $0 | XFOR, DCTH | New Holdings | 16 Aug 2023, 11:30 |
| Q2 2023 | 21 | $277,226,466 | +$118,707,824 | -$150,100,243 | -$31,392,419 | QDEL, EOLS, ADMA, GLPG, AMLX | 13F-HR | 11 Aug 2023, 16:05 |
| Q1 2023 | 22 | $298,170,913 | +$78,474,539 | -$54,688,655 | +$23,785,884 | AMYT, GLPG, CTIC, ADMA, QDEL | 13F-HR | 12 May 2023, 16:02 |
| Q4 2022 | 19 | $237,711,369 | +$50,074,604 | -$110,954,146 | -$60,879,542 | AMYT, APEN, CTIC, ADMA, QDEL | 13F-HR | 14 Feb 2023, 12:46 |
| Q3 2022 | 19 | $222,441,000 | +$46,624,279 | -$27,037,263 | +$19,587,016 | AMYT, QDEL, CTIC, XERS, APEN | 13F-HR | 10 Nov 2022, 17:05 |
| Q2 2022 | 25 | $214,932,000 | +$61,686,621 | -$51,171,301 | +$10,515,320 | AMYT, CTIC, XERS, ADMA, AMRN | 13F-HR | 12 Aug 2022, 17:19 |
| Q1 2022 | 28 | $241,108,000 | +$65,544,802 | -$46,754,828 | +$18,789,974 | AMYT, CTIC, XERS, AMRN, OVID | 13F-HR | 16 May 2022, 09:15 |
| Q4 2021 | 23 | $217,913,000 | +$96,040,100 | -$81,132,472 | +$14,907,628 | AMYT, CTIC, XERS, ADMA, OVID | 13F-HR | 11 Feb 2022, 17:55 |
| Q3 2021 | 31 | $216,035,000 | +$86,038,848 | -$52,225,219 | +$33,813,629 | AMYT, CTIC, ADMS, GLPG, OVID | 13F-HR | 12 Nov 2021, 16:41 |
| Q2 2021 | 26 | $191,223,000 | +$45,505,149 | -$36,172,920 | +$9,332,229 | AMYT, CHMA, CTIC, ADMS, CBIO | Restatement | 13 Aug 2021, 19:33 |
| Q1 2021 | 29 | $185,124,000 | +$112,156,524 | -$61,168,306 | +$50,988,218 | AMYT, ADMS, CHMA, CBIO, KALV | 13F-HR | 14 May 2021, 16:18 |
| Q4 2020 | 21 | $130,625,000 | +$38,227,902 | -$31,234,565 | +$6,993,337 | LGND, AMYT, DMAC, AYTU, APEN | 13F-HR | 12 Feb 2021, 17:11 |
| Q3 2020 | 17 | $96,131,000 | +$47,930,351 | -$5,107,478 | +$42,822,873 | LGND, ISEE, AMYT, CTIC, CBIO | 13F-HR | 13 Nov 2020, 16:08 |
| Q2 2020 | 13 | $51,630,000 | +$2,977,851 | -$61,406,496 | -$58,428,645 | ISEE, LGND, CTIC, DMAC, CBIO | 13F-HR | 13 Aug 2020, 16:24 |
| Q1 2020 | 27 | $94,557,000 | +$43,268,603 | -$24,789,014 | +$18,479,589 | LGND, ISEE, CTIC, AMRN, AFMD | 13F-HR | 14 May 2020, 16:40 |
| Q4 2019 | 23 | $143,457,000 | +$37,529,651 | -$35,985,204 | +$1,544,447 | AMRN, ISEE, AFMD, OXFD, ADMS | 13F-HR | 13 Feb 2020, 16:12 |
| Q3 2019 | 26 | $103,032,000 | +$23,291,481 | -$51,254,090 | -$27,962,609 | AMRN, OXFD, BDSI, ENTA, NEOS | 13F-HR | 13 Nov 2019, 16:49 |
| Q2 2019 | 25 | $145,241,000 | +$21,545,916 | -$24,257,157 | -$2,711,241 | LGND, VNDA, AMRN, BDSI, ADMS | 13F-HR | 13 Aug 2019, 16:42 |
| Q1 2019 | 30 | $173,855,000 | +$78,533,040 | -$40,921,056 | +$37,611,984 | VNDA, AMRN, LGND, NEOS, APEN | 13F-HR | 14 May 2019, 16:24 |
| Q4 2018 | 22 | $113,865,000 | +$23,375,146 | -$43,458,716 | -$20,083,570 | AMRN, BDSI, BSTC, CPIX, APEN | 13F-HR | 13 Feb 2019, 17:19 |
| Q3 2018 | 31 | $171,016,000 | +$44,126,187 | -$110,444,140 | -$66,317,953 | AMRN, APEN, BSTC, BDSI, CTIC | Restatement | 28 Nov 2018, 10:49 |
| Q2 2018 | 25 | $164,570,000 | +$34,480,427 | -$64,103,677 | -$29,623,250 | BSTC, CTIC, APEN, AMRN, VNDA | 13F-HR | 13 Aug 2018, 19:01 |
| Q1 2018 | 30 | $186,623,000 | +$66,652,796 | -$43,776,972 | +$22,875,824 | BSTC, CTIC, AMRN, VNDA, APEN | 13F-HR | 14 May 2018, 16:06 |
| Q4 2017 | 27 | $166,847,000 | +$55,589,455 | -$54,439,132 | +$1,150,323 | VIVE, BSTC, APEN, VNDA, ENTA | 13F-HR | 13 Feb 2018, 16:52 |
| Q3 2017 | 22 | $169,648,000 | +$44,379,578 | -$63,433,263 | -$19,053,685 | VIVE, ENTA, PCRX, SCTL, NVLNF | 13F-HR | 13 Nov 2017, 17:10 |
| Q2 2017 | 27 | $185,191,000 | +$56,888,016 | -$57,540,255 | -$652,239 | VIVE, ENTA, NVLNF, SCTL, VNDA | 13F-HR | 14 Aug 2017, 11:44 |
| Q1 2017 | 21 | $177,452,000 | +$32,726,142 | -$32,910,971 | -$184,829 | SCTL, VIVE, NVLNF, SCLN, Aegerion Pharmaceuticals, Inc. | 13F-HR | 12 May 2017, 16:16 |
| Q4 2016 | 23 | $167,888,000 | +$98,888,927 | -$48,031,417 | +$50,857,510 | SCTL, Aegerion Pharmaceuticals, Inc., ALR, SCLN, VIVE | 13F-HR | 10 Feb 2017, 15:42 |
| Q3 2016 | 17 | $122,629,000 | +$60,039,183 | -$58,925,480 | +$1,113,703 | TBRA, VIVE, Aegerion Pharmaceuticals, Inc., ALR, QLTI | 13F-HR | 14 Nov 2016, 12:08 |
| Q2 2016 | 23 | $97,537,000 | +$43,661,646 | -$41,328,070 | +$2,333,576 | SCLN, Viveve Medical, Inc, Aegerion Pharmaceuticals, Inc. (NOTES), VNDA, TBRA | Restatement | 11 Aug 2016, 11:44 |
| Q1 2016 | 19 | $84,794,000 | +$21,017,098 | -$11,370,384 | +$9,646,714 | SCLN, VNDA, VCEL, PTIE, TBRA | 13F-HR | 11 May 2016, 12:36 |
| Q4 2015 | 13 | $85,361,000 | $0 | $0 | $0 | VNDA, CTIC, SCLN, TBRA, SGNT | 13F-HR | 11 Feb 2016, 13:56 |